Hyloris Pharmaceuticals S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HYL.BR research report →
About the company
Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and bringing to market pharmaceutical products designed to fulfill critical unmet medical needs. The company's focus areas include cardiovascular health, oncology, women's health, and other significant therapeutic domains. Its cardiovascular portfolio features treatments for conditions such as atrial fibrillation, acute coronary syndrome, advanced and congestive heart failure, and coronary heart disease.
- CEO
- Thomas Jacobsen
- IPO
- 2020
- Employees
- 49
- HQ
- Liège, BE
Price Chart
- Market Cap
- $127.68M
- P/E
- -25.47
- P/S
- 21.14
- P/B
- 4.71
- EV/EBITDA
- -30.19
- Div Yield
- 0.00%
- Gross Margin
- 96.90%
- Op Margin
- -84.62%
- Net Margin
- -82.51%
- ROE
- -17.13%
- ROIC
- -17.88%
- Revenue
- $7.21M · -28.23%
- Net Income
- $-6,334,000 · 0.13%
- EPS
- $-0.23 · -4.55%
- Op Income
- $-9,335,000
- FCF YoY
- 1.98%
- 52W High
- $8.40
- 52W Low
- $4.51
- 50D MA
- $5.14
- 200D MA
- $6.00
- Beta
- 0.65
- Avg Volume
- 5.45K
Get TickerSpark's AI analysis on HYL.BR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HYL.BR coverage
Recent articles, reports, and earnings notes.
No research on HYL.BR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HYL.BR report →Similar companies
Peers in the same neighborhood.